Willis Ray Wolfe Jr.

Array ( [id] => 16238206 [patent_doc_number] => 20200255440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => ETHYNYL DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/865233 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421869 [patent_doc_number] => 20200347067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/863770 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 5325 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19910204 [patent_doc_number] => 12286400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-29 [patent_title] => Isofagomine salts, methods of use and formulations [patent_app_type] => utility [patent_app_number] => 17/605979 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 20503 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16390929 [patent_doc_number] => 20200331870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => MCL-1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/857021 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702814 [patent_doc_number] => 20220202820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS [patent_app_type] => utility [patent_app_number] => 17/604109 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702814 [patent_doc_number] => 20220202820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS [patent_app_type] => utility [patent_app_number] => 17/604109 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398684 [patent_doc_number] => 20200339542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/847975 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704318 [patent_doc_number] => 10954238 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-03-23 [patent_title] => Substituted naphthyridinone compounds useful as T cell activators [patent_app_type] => utility [patent_app_number] => 16/843024 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 183608 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655311 [patent_doc_number] => 20220175776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS [patent_app_type] => utility [patent_app_number] => 17/602355 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734645 [patent_doc_number] => 20220220104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/600900 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444845 [patent_doc_number] => 10836757 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-17 [patent_title] => Polymorphic forms of metopimazine [patent_app_type] => utility [patent_app_number] => 16/838402 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24428 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17953466 [patent_doc_number] => 11479557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Inhibitors of the menin-MLL interaction [patent_app_type] => utility [patent_app_number] => 16/837421 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 23 [patent_no_of_words] => 74236 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16799107 [patent_doc_number] => 10994023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Pyrrolobenzodiazepines and conjugates thereof [patent_app_type] => utility [patent_app_number] => 16/837336 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 37993 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343478 [patent_doc_number] => 20200308128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/835102 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931701 [patent_doc_number] => 12304898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Quinolyl-containing compound and pharmaceutical composition, and use thereof [patent_app_type] => utility [patent_app_number] => 17/594039 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14942 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 488 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16769806 [patent_doc_number] => 10980889 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-04-20 [patent_title] => C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors [patent_app_type] => utility [patent_app_number] => 16/831579 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68872 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17889833 [patent_doc_number] => 11452780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Mtorc1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/828774 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 58057 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 701 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670877 [patent_doc_number] => 20220184044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => USE OF RIFAXIMIN ON CIRCULATING AGED NEUTROPHILS IN SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 17/441840 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844855 [patent_doc_number] => 11434207 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => P2X4 receptor antagonist [patent_app_type] => utility [patent_app_number] => 16/826877 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40493 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 1397 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770799 [patent_doc_number] => 10981887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Benzothiophene estrogen receptor modulators [patent_app_type] => utility [patent_app_number] => 16/824290 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 22855 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16824290 [rel_patent_id] =>[rel_patent_doc_number] =>)